Edwards Lifesciences stock (US28176E1082): Q1 2026 sales lift on TAVR and TMTT growth

Edwards Lifesciences reports higher Q1 2026 sales and earnings, driven by Transcatheter Aortic Valve Replacement and Transcatheter Mitral and Tricuspid Therapies.

Edwards Lifesciences has reported stronger first?quarter 2026 results, with net sales rising to $1.65 billion and earnings per share climbing to $0.66, as growth in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) underpins the performance. The company’s net income attributable to Edwards increased to $380.7 million from $358.0 million a year earlier, reflecting solid demand for its structural heart therapies despite higher litigation expenses and a one?time impairment charge tied to an earlier medical?device investment, according to a recent 10?Q filing summary published by StockTitan on May 9, 2026.

Quarterly revenue growth of about 16–17% year?on?year, depending on the metric used, has been highlighted by MarketBeat and Investing.com, which note that Edwards’ Q1 2026 revenue of roughly $1.65 billion beat consensus estimates of around $1.6 billion and that adjusted EPS of about $0.78 exceeded the forecast of $0.73. Analyst commentary cited by Investing.com points to double?digit earnings?per?share growth and margin expansion expectations from 2026 onward, underpinned by Edwards’ leading position in the TAVR market and its expansion into the TMTT segment, where the company has set an ambitious $2 billion sales target by 2030.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Edwards Lifesciences Corporation
• Sector/industry: Medical devices, cardiovascular therapies
• Headquarters/country: Irvine, California, United States
• Core markets: United States, Europe, Asia?Pacific
• Key revenue drivers: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), critical?care monitoring
• Home exchange/listing venue: New York Stock Exchange (NYSE: EW)
• Trading currency: U.S. dollar (USD)

Edwards Lifesciences: core business model

Edwards Lifesciences designs, manufactures and sells medical devices focused on structural heart disease and critical?care monitoring. The company’s core business model centers on minimally invasive therapies that treat valvular heart disease, particularly aortic stenosis and mitral and tricuspid valve disorders, as well as hemodynamic monitoring systems used in intensive care and operating rooms. Edwards’ products are sold to hospitals, clinics and other healthcare providers worldwide, with a strong presence in the United States, Europe and parts of Asia?Pacific.

The company generates recurring revenue through a combination of high?margin devices, disposables and service contracts. Its structural heart portfolio includes transcatheter heart valves and delivery systems, while its critical?care segment supplies pressure?monitoring catheters, sensors and monitoring platforms. This mix of capital equipment and consumables helps Edwards maintain relatively stable cash flows and supports long?term growth as the global population ages and the prevalence of cardiovascular disease rises.

Main revenue and product drivers for Edwards Lifesciences

The primary revenue driver for Edwards Lifesciences is its Transcatheter Aortic Valve Replacement (TAVR) business, which has established the company as a market leader in minimally invasive aortic valve therapy. TAVR procedures are used to treat severe aortic stenosis in patients who are at high or intermediate surgical risk, and the procedure has gained broad adoption in the United States and Europe. Edwards’ SAPIEN family of transcatheter heart valves and associated delivery systems account for a significant share of the company’s sales and operating income.

Second, the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment is emerging as a key growth engine. Edwards is expanding its portfolio of devices for mitral and tricuspid valve repair and replacement, including transcatheter edge?to?edge repair systems and annuloplasty technologies. The company has publicly targeted $2 billion in annual TMTT sales by 2030, signaling its intent to replicate the success it has achieved in TAVR. In addition, Edwards’ critical?care monitoring business, which includes hemodynamic monitoring platforms and disposables, contributes steady revenue and benefits from ongoing demand in intensive care units and operating rooms.

Why Edwards Lifesciences matters for US investors

For US investors, Edwards Lifesciences represents exposure to a high?margin, innovation?driven segment of the medical?device industry with strong secular tailwinds from an aging population and rising cardiovascular disease prevalence. The company’s listing on the New York Stock Exchange under the ticker EW provides direct access to a US?domiciled firm that derives a substantial portion of its sales from the United States, the world’s largest medical?device market. Edwards’ leadership in TAVR and its strategic push into TMTT position it to benefit from continued procedural growth and favorable reimbursement trends in the United States.

Moreover, Edwards’ financial profile—characterized by high gross margins, solid earnings growth and a strong balance sheet—aligns with the preferences of many growth?oriented and quality?focused investors. The company’s recent quarterly results, which show double?digit revenue growth and earnings expansion, reinforce its position as a core holding for investors seeking exposure to structural heart therapies and critical?care monitoring. At the same time, US investors should be mindful of regulatory, reimbursement and competitive risks that could affect future performance.

Conclusion

Edwards Lifesciences has delivered stronger first?quarter 2026 results, with sales and earnings rising on the back of growth in Transcatheter Aortic Valve Replacement and Transcatheter Mitral and Tricuspid Therapies. The company’s leadership in structural heart therapies, combined with its expanding TMTT portfolio and solid critical?care monitoring business, supports a growth?oriented profile that may appeal to US investors seeking exposure to high?margin medical?device innovation. At the same time, investors should weigh the company’s valuation, regulatory and competitive risks when considering the stock.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.